WEKO3
-
RootNode
アイテム
Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice
http://hdl.handle.net/10458/0002000111
http://hdl.handle.net/10458/0002000111a197c88a-8038-426b-ad04-b1f31f0ad532
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
著者最終原稿 (459 KB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-10-24 | |||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||
| タイトル | Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| キーワード | adult T-cell leukemia/lymphoma | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| キーワード | antibody therapy | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| キーワード | CC chemokine receptor 4 | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| キーワード | mogamulizumab | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||
| キーワード | retrospective | |||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||
| 著者 |
関根, 雅明
× 関根, 雅明× 久冨木, 庸子× 亀田, 拓郎× Takeuchi, Masanori
× Toyama, Takanori
× Kawano, Noriaki
× Maeda, Kouichi
× Sato, Seiichi
× Ishizaki Junzo
× Kawano, Hiroshi
× 上運天, 綾子× 秋月, 渓一× Tahira, Yuki× 下田, 晴子× 幣, 光太郎× 日髙, 智徳× 北中, 明× Yamashita, Kiyoshi
× Matsuoka, Hitoshi
× 下田, 和哉 |
|||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||
| 内容記述 | Objective The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. Method We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. Results Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab. Conclusion In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients. |
|||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 内容記述 | ||||||||||||||||||||||||
| 内容記述タイプ | Other | |||||||||||||||||||||||
| 内容記述 | Sekine, M, Kubuki, Y, Kameda, T, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017; 98: 501–507. https://doi.org/10.1111/ejh.12863 | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 書誌情報 |
en : European Journal of Haematology 巻 98, 号 5, p. 501-507, 発行日 2017-02-02 |
|||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||
| 出版者 | Wiley | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| ISSN | ||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||
| 収録物識別子 | 0902-4441 | |||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||
| 関連タイプ | isVersionOf | |||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1111/ejh.12863 | |||||||||||||||||||||||
| 権利 | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 権利情報 | © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd | |||||||||||||||||||||||
| 著者版フラグ | ||||||||||||||||||||||||
| 出版タイプ | AO | |||||||||||||||||||||||
Share
Cite as
関根, 雅明, 久冨木, 庸子, 亀田, 拓郎, Takeuchi, Masanori, Toyama, Takanori, Kawano, Noriaki, Maeda, Kouichi, Sato, Seiichi, Ishizaki Junzo, Kawano, Hiroshi, 上運天, 綾子, 秋月, 渓一, Tahira, Yuki, 下田, 晴子, 幣, 光太郎, 日髙, 智徳, 北中, 明, Yamashita, Kiyoshi, Matsuoka, Hitoshi, 下田, 和哉, 2017, Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice: Wiley, 501–507 p.
Loading...
